16Oct 2018

ROLE OF MALONDIALDEHYDE(MDA) AND NITRIC OXIDE (NO) IN PATIENTS WITH BREAST CANCER DISEASES.

  • Department Of Health Community Techniques, Al-Furat Al-Awsat Technical University , Technical Institute/ Samawa.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Breast cancer is a malignant tumor that begins in the breast cells . Malignant tumor is a group of cancer cells that able to grow into surrounding tissues or spread (metastasize) to faraway regions of the body. The disease take place nearly fully in women ,but men can get it, also. Malondialdehyde (MDA) is end-products of lipid hydroperoxide decomposition and one of many low molecular weight and is the mostly measured as an indicator of lipid peroxidation . Aim: This study aims to investigate the relation between Malondialdehyde (MDA) and nitric oxide (NO level with the development of Breast Cancer. Methods: Plasma of Malondialdehyde (MDA) and nitric oxide (NO) were determined in 46 patients with Breast cancer and 21 healthy subjects as control group using by the colorimetric method,. All results were statistically analyzed. Results: A highly significant increase was found in the serum level MDA in patients with Breast Cancer compared to control (P < 0.05). serum levels of NO were significantly increased in the patient group (P < 0.05) compared to control. Conclusion: The results of the present study provide evidence that the family history has a clear link with breast cancer risk while does not have such a link with smoking or lodging. High levels of oxidative/nitrosative stress statues were presented in patients with breast cancer.

  1. Amin KA, Mohamed BM, El-Wakil MA, Ibrahem SO (2012). Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers. J Breast Cancer, 15, 306-12.
  2. BadidN, Ahmed FZ, MerzoukH, et al (2010). Oxidant/ antioxidantstatus,lipidsandhormonalprofileinoverweight women with breast cancer.PatholOncol Res, 16,159-67.
  3. CapassoI,EspositoE,PentimalliF,(2011).Metabolic syndrome affectsbreastcancerriskinpostmenopausal women:national cancer institute of Naples experience. Cancer BiolTher, 10, 1240-3.
  4. Cook JA, Gius D, Wink DA, et al (2004). Oxidative stress, redox, and the tumor microenvironment. SeminRadiatOncol, 14, 259-66.
  5. Demirci S, Ozsaran Z, Celik HA, Aras(2011). The interaction between antioxidant status and cervical cancer: a case control study.Tumori, 97, 290-5.
  6. Emerit J, Beaumont C, Trivin F. (2001). Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother, 55, 333-9.
  7. Furberg AS, Veier?d MB, WilsgaardT, Bernstein L, Thune? I (2004). Serum high-density lipoprotein cholesterol, metabolic profile,andbreastcancer risk.JNCIJNatlCancer Inst, 96,1152-60.
  8. G?nen? A,ErtenD,AslanS,etal(2006).Lipidperoxidation andantioxidant statusinbloodandtissueofmalignantbreast tumor and benign breast disease. Cell BiolInt,30, 376-80.
  9. HimmetogluS,DincerY,ErsoyYE,etal(2009).DNAoxidationand antioxidant status in breast cancer. J Investig Med,57, 720-3.
  10. Kumaraguruparan R, Subapriya R, Kabalimoorthy J, Nagini S. (2002). Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast.ClinBiochem, 35, 275-9
  11. Koh E, Noh SH, Lee YD, Lee HY, Han JW, Lee HW, et al(1999)Differential expression of nitric oxide synthase in human stomach cancer. Cancer Lett, 146,173-80.
  12. Thomsen LL, Miles DW, Happerfield LC, et al (1995). Nitric oxidesynthaseactivityinhumanbreast BrJCancer, 72, 41-4
  13. Jansson OT, Morcos E, Brundin L, et al (1998). Nitric oxide synthase in human renal cell carcinoma.J Urol, 160, 556-60.
  14. InamdarP, Mehta G (2011). Correlation between obesity and highdensitylipoproteincholesterol(hdl-c)inbreastcancer patients of Southern Rajasthan.Indian J SurgOncol, 2, 118-21.
  15. Liu X, Zhao J, Zheng R (2003). DNA damage of tumor- associated lymphocytes and total antioxidant capacity in cancerous patientsMutat Res, 539, 1-8.
  16. Hanahan S. andWeinberg R. A. (2000). The hallmarks of cancer. Cell, 100: 57-70.

[Ashwaq Audah. (2018); ROLE OF MALONDIALDEHYDE(MDA) AND NITRIC OXIDE (NO) IN PATIENTS WITH BREAST CANCER DISEASES. Int. J. of Adv. Res. 6 (Oct). 1072-1076] (ISSN 2320-5407). www.journalijar.com

Ashwaq audah
Samawa technical institute

DOI:

Article DOI: 10.21474/IJAR01/7908      
DOI URL: https://dx.doi.org/10.21474/IJAR01/7908

Download Full Paper

Download PDF No. of Downloads: 17 | No. of Views: 70